Efficacy and tolerability of rosuvastatin and atorvastatin when force-titrated in patients with primary hypercholesterolemia: Results from the ECLIPSE study

Cardiology

Volumn 111, Issue 4, 2008, Pages 219-228

  Faergeman, Ole ^a   Hill, Laurie ^b   Windler, Eberhard ^c   Wiklund, Olov ^d   Asmar, Roland ^e   Duffield, Emma ^f   Sosef, Froukje ^g  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b Brampton Cardiopulmonary Services   (Canada)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^e Institut Cardiovasculaire   (France)

^f ASTRAZENECA   (United Kingdom)

^g ASTRAZENECA R AND D   (Sweden)

Author keywords

Atorvastatin; Hypercholesterolemia; Low density lipoprotein cholesterol; Rosuvastatin

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ATORVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIET RESTRICTION; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEMATURIA; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; LIPID BLOOD LEVEL; LIVER DISEASE; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MUSCLE DISEASE; MYALGIA; OPEN STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; RHINOPHARYNGITIS; RISK BENEFIT ANALYSIS; RISK REDUCTION; SIDE EFFECT; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

AGED; CANADA; CHOLESTEROL, LDL; CORONARY DISEASE; EUROPEAN UNION; FEMALE; FLUOROBENZENES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PYRIMIDINES; PYRROLES; RISK ASSESSMENT; RISK FACTORS; SULFONAMIDES;

EID: 54949141395     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000127442     Document Type: Article

References (29)

1. Balbisi EA: Management of hyperlipidemia: new LDL-C targets for persons at high-risk for cardiovascular events. Med Sci Monit 2006;12:RA34-RA39.
2. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
3. Scandinavian Simvastatin Survival Study (4S) Group: Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
4. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-1307.
5. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-1009.
6. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R, Cholesterol Treatment Trialists' (CTT) Collaborators: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-1278.
7. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
8. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, Ebrahim S, Faergeman O, Graham I, Mancia G, Cats VM, Orth-Gomer K, Perk J, Pyorala K, Rodicio JL, Sans S, Sansoy V, Sechtem U, Silber S, Thomsen T, Wood D, European Society of Cardiology Committee for Practice Guidelines: European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2003;10:S1-S10.
9. Grundy SM, Cleeman JI, Merz CN, Brewer HB, Clark LT, Hunninghake DB, Pasternak RC, Smith SC, Stone NJ, National Heart, Lung, and Blood Institute, American College of Cardiology Foundation, American Heart Association: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-239.
10. Pearson TA, Laurora I, Chu H, Kafonek S: The lipid treatment assessment project (LTAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000;160:459-467.
11. EUROASPIRE II Study Group: Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001;22:554-572.
12. Foley KA, Simpson RJ, Crouse JR 3rd, Weiss TW, Markson LE, Alexander CM: Effectiveness of statin titration on low-density lipoprotein cholesterol goal attainment in patients at high risk of atherogenic events. Am J Cardiol 2003;92:79-81.
13. Schwandt P, Brady AJ: Achieving lipid goals in Europe: how large is the treatment gap? Expert Rev Cardiovasc Ther 2004;2:431-449.
14. Van Ganse E, Laforest L, Alemao E, Davies G, Gutkin S, Yin D: Lipid-modifying therapy and attainment of cholesterol goals in Europe: the Return on Expenditure Achieved for Lipid Therapy (REALITY) study. Curr Med Res Opin 2005;21:1389-1399.
15. Grundy SM: Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy. Circulation 2002;106:2526-2529.
16. Bourgault C, Davignon J, Fodor G, Gagne C, Gaudet D, Genest J, Lavoie MA, Leiter L, McPherson R, Senecal M, Marentette M, Sebaldt RJ: Statin therapy in Canadian patients with hypercholesterolemia: the Canadian Lipid Study - Observational (CALIPSO). Can J Cardiol 2005;21:1187-1193.
17. Cziraky MF, Willey VJ, McKenney JM, Kamat SA, Fisher MD, Guyton JR, Jacobson TA, Davidson MH: Statin safety: an assessment using an administrative claims database. Am J Cardiol 2006;97:61C-68C.
18. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
19. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK, Treating to New Targets (TNT) Investigators: Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-1435.
20. Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Bendiksen FS, Lindahl C, Szarek M, Tsai J, Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group: High-dose atorvastatin vs. usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005;294:2437-2445.
21. Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, Davignon J, Erbel R, Fruchart JC, Tardif JC, Schoenhagen P, Crowe T, Cain V, Wolski K, Goormastic M, Tuzcu EM, ASTEROID Investigators: Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006;295:1556-1565.
22. Cohen JC, Boerwinkle E, Mosley TH, Hobbs HH: Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006;354:1264-1272.
23. Brown MS, Goldstein JL: A receptor-mediated pathway for cholesterol homeostasis. Science 1986;232:34-47.
24. Gotto AM, Whitney E, Stein EA, Shapiro DR, Clearfield M, Weis S, Jou JY, Langendorfer A, Beere PA, Watson DJ, Downs JR, de Cani JS: Relation between baseline and on-treatment lipid parameters and first acute major coronary event in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation 2000;101:477-484.
25. Wang TD, Chen WJ, Chien KL, Seh-Yi Su SS, Hsu HC, Chen MF, Liau CS, Lee YT: Efficacy of cholesterol levels and ratios in predicting future coronary heart disease in a Chinese population. Am J Cardiol 2001;88:737-743.
26. Qureshi AI, Giles WH, Croft JB, Guterman LR, Hopkins LN: Apolipoproteins A-I and B and the likelihood of non-fatal stroke and myocardial infarction - data from the Third National Health and Nutrition Examination Survey. Med Sci Monit 2002;8:CR311-CR316.
27. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L, INTERHEART Study Investigators: Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364:937-952.
28. Faergeman O: Introduction: apolipoproteins and guidelines for prevention of cardiovascular disease. J Intern Med 2006;259:434-436.
29. Jones PH, Hunninghake DB, Ferdinand KC, Stein EA, Gold A, Caplan RJ, Blasetto JW, Statin Therapies for Elevated Lipid Levels Compared Across Doses to Rosuvastatin Study Group: Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial. Clin Ther 2004;26:1388-1399.